Clinical Trial Update: Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating tasquinimod in patients with myelofibrosis who are refractory to or intolerant of JAK2 inhibitors and the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Tasquinimod (tasquinimod)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: RECRUITING